EP 1943261 A2 20080716 - DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND
Title (en)
DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND
Title (de)
MIT EINER NICHTNUKLEOTIDISCHEN, P2Y12-REZEPTOR-ANTAGONISTISCHEN VERBINDUNG BESCHICHTETE ARZNEIMITTEL ELUIERENDE STENTS
Title (fr)
STENTS POUR ÉLUTION DE MÉDICAMENT AVEC COMPOSÉ ANTAGONISTE RÉCEPTEUR P2Y12 NON NUCLÉOTIDE
Publication
Application
Priority
- US 2006043089 W 20061102
- US 26794105 A 20051104
- US 2006017781 W 20060505
Abstract (en)
[origin: WO2007056217A2] This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The present invention also provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Y<SUB>12</SUB> receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged blood vessel, a therapeutically effective amount of the P2Y<SUB>12</SUB> receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y<SUB>12</SUB> receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting thrombus formation, inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
IPC 8 full level
C07H 19/20 (2006.01)
CPC (source: EP)
A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61F 2/82 (2013.01); A61F 2250/0067 (2013.01)
Citation (search report)
See references of WO 2007056217A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2007056217 A2 20070518; WO 2007056217 A3 20071122; EP 1943261 A2 20080716
DOCDB simple family (application)
US 2006043089 W 20061102; EP 06827504 A 20061102